The two vaccines for respiratory syncytial virus (RSV) were approved by the FDA for older adults in May.
1 Aug 2023
The CDC's Advisory Committee on Immunization Practices recommended in June that adults ages 60 years and older may receive a single dose of an RSV vaccine, using shared clinical decision making.
1 Oct 2023
A recent study raises doubts about whether oseltamivir should be promoted as a way to prevent hospitalization in low-risk patients.
1 Nov 2023
An industry trial found that coadministration of an mRNA COVID-19 booster vaccine with a first dose of recombinant zoster vaccine was immunologically noninferior to spacing the shots two weeks apart, with a similar safety and reactogenicity profile.
27 Jun 2023
The results from a large ongoing phase 3 trial show success in protection from respiratory syncytial virus (RSV)-associated lower respiratory tract illness on two important primary endpoints, although reductions in hospitalization and death have yet to be shown.
11 Apr 2023
This month's issue addresses new vaccines, screening for anxiety, and detecting and treating loneliness.
1 Oct 2023
The FDA further limited use of the Johnson & Johnson (Janssen) vaccine and scheduled advisory committee meetings on other vaccine questions. Two non-mRNA vaccines showed effectiveness, and other studies looked at antibody prevalence, home test accuracy, and long-term symptoms.
10 May 2022
This column reviews recent recalls, alerts, and approvals.
1 Jun 2023
The annual immunization schedule consolidates and summarizes updates to the recommendations of the Advisory Committee on Immunization Practices (ACIP).
14 Feb 2023
CDC and FDA weigh in on safety of bivalent vaccine; research examines COVID-19 sequelae, omicron variants
The CDC and FDA said an observed association of ischemic stroke with the Pfizer-BioNTech bivalent booster is very unlikely to represent a true clinical risk. New studies reported on symptoms a year after mild COVID-19 and estimated protection against the omicron variants.
24 Jan 2023